Private
Funding Agency
Otsuka Pharmaceutical
Title
A Multi-enter, Phase 2, Single-Arm, open-label exploratory study of individually-optimized conditioning using pharmacokinetics (PK)-direct dose adjustment of once daily intravenous busulfan. Followed by autologous hematopoietic stem cell transplant in su
Status
Active
Period
9/2009 - Present
Role
Principal Investigator
Grant Detail
Funding Agency
FlaxoSmithKline
Title
Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in relapsed or refractory DLBCL
Status
Active
Period
11/2009 - Present
Role
Co-Investigator
Grant Detail
Funding Agency
Otsuka Pharmaceutical
Title
A Phase 2a study of once daily intravenous busulfan with bortezomib. Followed by an autologous hematopoietic stem cell transplant (HSCT) in subjects with relapsed multiple myeloma after prior autologous HSCT
Status
Active
Period
4/2010 - Present
Role
Co-Investigator
Grant Detail
Funding Agency
Kabi-Pharmacia
Title
A Randomized Phase III Double-Blind Study of the Use of Linomide vs. Placebo Following Autologous Bone Marrow Transplantation for the First or Subsequent Remission Complete Remission in Acute Myelogenous Leukemia
Status
Active
Period
11/1993 - Present
Role
Principal Investigator
Grant Detail
Funding Agency
Independent research
Title
A multicenter phase II study of rituximab in patients with CD20 positive intermediate-grade and select high-grade non-hodgkin's lymphoma who have relapsed after high-dose chemotherapy and autologous stem cell transplantation.
Status
Active
Period
5/2000 - Present
Role
Co-Investigator
Grant Detail
A multicenter phase II study of rituximab in patients with CD20 positive intermediate-grade and select high grade non-Hodgkin's lymphoma who have relapsed after high-dose chemotherapy and autologous stem cell transplantation.
Funding Agency
CellPro, Inc.
Title
A Prospective Randomized Phase III Study Using CEPRATE SC Stem Cell Concentrator to Concentrate Hematopoietic Progenitors for Use in hematopoietic Support After High Dose Chemotherapy
Status
Active
Period
7/1992 - Present
Role
Principal Investigator
Grant Detail
Funding Agency
Human Genome Sciences
Title
A multicenter, rising-dose, randomized double-blinded study vehicle controlled study of intravenous KGF-2 in subjects at risk of developing mucositis secondary to the action of conditioning regimens for autologous hematopoietic stem cell transplantation.
Status
Active
Period
3/2000 - Present
Role
Principal Investigator
Grant Detail
A multicenter, rising-dose, randomized double-blinded study vehicle controlled study of intravenous KGF-2 in subjects at risk of developing mucositis secondary to the action of conditioning regimens for autologous hematopoietic stem cell transplantation.
